Follow-up Study of Rituximab Treatment for Nephrotic Syndrome in Children Aged 1 to 18 Years

What this Trial Is About

This research focuses on children diagnosed with refractory nephrotic syndrome who received rituximab RTX treatment and were followed for at least one year. It aims to evaluate the clinical effectiveness and safety of RTX by comparing relapse rates, steroid and immunosuppressant use, and adverse reactions before and after treatment. Additionally, the study analyzes risk factors for disease recurrence and assesses growth indicators and the economic impact of RTX treatment. Children in this study received RTX doses of 375 mgm2, administered either as a preventive measure based on B cell reconstitution or after a relapse occurred. The treatment involves regular monitoring of B lymphocyte levels to determine the need for 1 to 4 doses of RTX. Two groups are observed one receiving prophylactic RTX and the other receiving RTX after relapse. Participants medical records were reviewed for personal and clinical data, including relapse-free survival over one year and treatment effectiveness across different groups. Researchers monitored adverse drug reactions, growth, and steroidimmunosuppressant reduction or withdrawal. The study spans from March 2020 to March 2026, with follow-up lasting at least one year to measure outcomes and safety.

Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children